Lebwohl David 4
4 · Intellia Therapeutics, Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
Lebwohl David
EVP, Chief Medical Officer
Transactions
- Award
Common Stock
2024-03-01+38,701→ 93,073 total - Award
Stock Option (right to buy)
2024-03-01+55,855→ 55,855 totalExercise: $32.66Exp: 2034-02-28→ Common Stock (55,855 underlying)
Footnotes (2)
- [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F2]This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.